Insight Capital Research & Management Inc. lowered its position in NuVasive, Inc. (NASDAQ:NUVA) by 44.5% during the second quarter, according to its most recent filing with the SEC. The firm owned 26,909 shares of the medical device company’s stock after selling 21,580 shares during the period. NuVasive makes up about 1.2% of Insight Capital Research & Management Inc.’s investment portfolio, making the stock its 28th largest position. Insight Capital Research & Management Inc. owned approximately 0.05% of NuVasive worth $2,070,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of the company. Westside Investment Management Inc. acquired a new position in NuVasive during the first quarter worth about $109,000. FNY Partners Fund LP acquired a new position in NuVasive during the first quarter worth about $112,000. Neuburgh Advisers LLC boosted its position in shares of NuVasive by 18.3% in the first quarter. Neuburgh Advisers LLC now owns 1,552 shares of the medical device company’s stock worth $116,000 after buying an additional 240 shares in the last quarter. SpiderRock Advisors LLC purchased a new position in shares of NuVasive during the first quarter worth about $124,000. Finally, Glen Harbor Capital Management LLC boosted its position in shares of NuVasive by 18.3% in the first quarter. Glen Harbor Capital Management LLC now owns 2,134 shares of the medical device company’s stock worth $159,000 after buying an additional 330 shares in the last quarter.
Shares of NuVasive, Inc. (NASDAQ:NUVA) traded up 4.30% during trading on Friday, hitting $66.63. The company had a trading volume of 1,695,893 shares. NuVasive, Inc. has a 52 week low of $56.70 and a 52 week high of $81.68. The stock has a market capitalization of $3.39 billion, a P/E ratio of 104.93 and a beta of 1.06. The firm’s 50 day moving average is $73.76 and its 200-day moving average is $74.02.
NuVasive (NASDAQ:NUVA) last released its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.46 EPS for the quarter, topping the consensus estimate of $0.44 by $0.02. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. The company had revenue of $260.60 million for the quarter, compared to the consensus estimate of $261.95 million. During the same period last year, the business posted $0.40 EPS. NuVasive’s quarterly revenue was up 10.3% on a year-over-year basis. Equities research analysts anticipate that NuVasive, Inc. will post $2.00 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “NuVasive, Inc. (NUVA) Position Reduced by Insight Capital Research & Management Inc.” was first reported by Stock Observer and is the property of of Stock Observer. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.thestockobserver.com/2017/08/12/insight-capital-research-management-inc-sells-21580-shares-of-nuvasive-inc-nuva-updated-updated.html.
A number of equities analysts recently issued reports on NUVA shares. TheStreet upgraded NuVasive from a “c+” rating to a “b” rating in a report on Wednesday, May 3rd. Zacks Investment Research raised NuVasive from a “sell” rating to a “hold” rating in a research report on Thursday, April 27th. BidaskClub raised NuVasive from a “hold” rating to a “buy” rating in a research report on Wednesday, July 19th. Barclays PLC increased their price target on NuVasive from $80.00 to $82.00 and gave the company an “overweight” rating in a research report on Monday, April 24th. Finally, Royal Bank Of Canada increased their price target on NuVasive from $76.00 to $85.00 and gave the company an “outperform” rating in a research report on Tuesday, June 6th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. NuVasive has a consensus rating of “Buy” and an average price target of $81.18.
In related news, EVP Peter Michael Leddy acquired 7,850 shares of NuVasive stock in a transaction on Tuesday, August 1st. The stock was acquired at an average price of $63.88 per share, for a total transaction of $501,458.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.70% of the stock is owned by company insiders.
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.